Ex vivo DNA damage response assays in tumor slices to predict the | 978
Translational Medicine

Translational Medicine
Open Access

ISSN: 2161-1025

+44 1223 790975

Ex vivo DNA damage response assays in tumor slices to predict therapy response

2nd International Conference on Translational & Personalized Medicine

August 05-07, 2013 Holiday Inn Chicago-North Shore, IL, USA

Dik C. Van Gent

Scientific Tracks Abstracts: Transl Med

Abstract :

One of the hallmarks of cancer is genomic instability, which has been studied extensively in tumor cell lines. It has been much more difficult to study how DNA damage response (DDR) pathways operate in living tumors. Therefore, we developed several techniques to grow short term tumor cell cultures or tumor slices ? ex vivo ? and study the DDR by inducing DNA damage in cultured tumor cells or slices. Several DNA repair proteins accumulate as visible foci on DNA double strand breaks (DSBs). We used this phenomenon to study accumulation of the general markers of DNA breaks (gamma-H2AX and 53BP1) and the homologous recombination repair pathway (RAD51) after DSB induction. BRCA1 or BRCA2 deficiency has been shown before to lead to a defect in RAD51 foci formation. We were able to show that BRCA1 deficient and proficient xenograft tumors could be discriminated well on the basis of this assay. We also screened human tumors and found that a BRCA1 deficient tumor metastasis was RAD51 foci deficient, while most sporadic tumors were proficient. Interestingly, we were also able to identify a sporadic tumor that was RAD51 foci deficient. This tumor slice also showed high sensitivity to PARP inhibitor treatment, another hallmark of BRCA1/2 deficient cells. Therefore, we conclude that we developed a robust assay for identifying BRCA-deficient tumors, which will be important to select patients for PARP inhibitor treatment. Furthermore, other therapeutic interventions can also be tested in this system, which maintains tumor slice integrity and proliferation for at least one week.

Biography :

Dik C. Van Gent did his Ph.D. at the Netherlands Cancer Institute (NKI) and postdoctoral studies at the National Institutes of Health (USA). He is now Associate Professor at the world-renowned DNA repair group at the Department of Genetics of the Erasmus MC Rotterdam, one of the largest university medical centers in The Netherlands. He has published more than 50 papers in reputed journals, including Cell, Science and Nature and serves as an editorial board member of ?DNA Repair? and ?Genome Integrity?.